Recently we compile a list of 12 best medical care actions to buy and maintain for 5 years. Eli Lilly and Company is one of them.
Eli Lilly and Company (Nyse: Lly) heads our list for being one of the The best medical care actions. He is a global biopharmaceutical leader and continues to expand his presence in diabetes, obesity, oncology, immunology and neurology. The company’s portfolio includes high -success medications such as Mounjaro and Zepbound for diabetes and obesity, as well as Donanemab for Alzheimer’s disease, backed by strong R&D capabilities and consistent commercial execution.
In September 2025, Lly announced plans for a manufacturing installation of $ 6.5 billion in Houston, Texas, one of the largest private investments in the city in recent years. The site will expand the production of small molecule medications, including orforglipron, its experimental oral GLP-1 receiver agonist by obesity. It is expected to be operational within five years, the installation will create several hundred jobs while reinforcing LLY’s commitment to next -generation obesity treatments.
Eli Lilly and Company (NYSE: Lly) is also looking for international growth, with plans to launch Orforglipron in India awaiting regulatory approval. This movement highlights the company’s strategy to capture the demand for oral medicines for weight loss in emerging markets. At the same time, the Corporation simplified its pipe by stopping the development of a medication that preserves muscle combined with Zepbound, choosing to focus resources on its most promising obesity assets.
Meanwhile, Lly strengthened her neurology portfolio as European regulators granted marketing authorization for Donanemab, advancing the company’s position in Alzheimer’s disease therapies. Financially, the firm reported strong international growth for Mounjaro, although US sales were slightly affected by isolated form challenges. However, the global demand for treatments based on Tirzepatidas remains robust, which supports an optimistic perspective for continuous expansion.
While we recognize Lray’s potential as an investment, we believe that certain AI actions offer greater upward potential and have less downward risk. If you are looking for an extremely undervalued action that also benefits significantly from the Trump era tariffs and the wave trend, see our free report on the The best short -term AI actions.
Read below: 30 actions that should double in 3 years and 11 hidden shares to buy now
Disclosure: None.
(Tagstotranslate) Eli Lilly and Company (T) Alzheimer’s disease
Source link